VA research updates: bone grafts, Alzheimer's, diabetes
The VA's Office of Research and Development has published three new research briefs that could significantly impact how Veterans receive treatment for bone injuries, Alzheimer's disease, and diabetes. These findings represent meaningful advances in medical care that may eventually translate into improved treatment options at VA medical facilities across the country.
VA researchers in Salt Lake City have developed a breakthrough in bone graft technology by incorporating low concentrations of copper into fluorapatite, a mineral used in synthetic bone grafts. Bone grafts frequently fail due to bacterial infection, and while copper has known antibacterial properties, previous attempts to use it in bone grafts proved toxic to the bone-growing cells called osteoblasts. The Salt Lake City team identified the precise copper concentration that successfully limits bacterial adhesion while preserving bone regeneration, potentially offering safer options for Veterans who need bone or dental implants following service-connected injuries or conditions.
A separate study conducted by VA researchers in San Diego and Greater Los Angeles examined the connection between depression and Alzheimer's disease and related dementias, analyzing 20 years of electronic health records from more than 700,000 Veterans. The findings revealed that Veterans diagnosed with depression before age 60 face more than 250 percent greater risk of developing Alzheimer's disease and related dementias compared to those without depression, while those diagnosed after age 60 still face a 70 percent higher risk. Importantly, this connection existed independently of traumatic brain injury or PTSD status, meaning depression itself appears to be a significant risk factor for cognitive decline.
Philadelphia VA researchers contributed to an international effort that created a more accurate genetic risk calculation for type 2 diabetes. The new scoring system draws on genetic data from 2.2 million people, including participants in the VA's Million Veteran Program, and provides improved accuracy for Veterans of European, African, mixed American, South Asian, and East Asian ancestries. This represents a substantial improvement over existing genetic risk scores, roughly 70 percent of which relied solely on genetic data from people of European ancestry, and the researchers have made this tool freely available for use worldwide.
For disabled Veterans, these research developments carry particular significance beyond their immediate medical applications. Many service-connected disabilities involve bone damage requiring grafts, and conditions like depression are prevalent among disabled Veterans who may already be managing multiple health challenges. The depression-Alzheimer's connection underscores why mental health treatment should be viewed not just as addressing current symptoms but as preventive care for future cognitive health, particularly for Veterans diagnosed with depression in their middle years.
The diabetes risk score matters because accurate risk prediction enables earlier intervention and better prevention strategies, which is especially important for Veterans managing service-connected conditions that may complicate diabetes treatment. While these are research findings rather than immediate policy changes, they represent the kind of evidence-based medicine that eventually shapes VA treatment protocols and clinical guidelines.
Veterans currently receiving treatment for depression should discuss cognitive screening with their VA providers, particularly those who were diagnosed before age 60. Those interested in diabetes prevention or who have family histories of the disease may want to ask their providers about genetic risk assessment options. Veterans can stay informed about VA research developments by visiting the Office of Research and Development website, and those with service-connected bone injuries, depression, or metabolic conditions should maintain regular contact with their VA care teams to ensure they benefit from emerging treatment advances as they become available in clinical practice.